These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 22008393)
1. Intravitreal ranibizumab, with or without filter? Montero JA; Ruiz-Moreno JM; Sanchis-Merino E Acta Ophthalmol; 2012 Aug; 90(5):e405-6. PubMed ID: 22008393 [No Abstract] [Full Text] [Related]
2. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. Saito M; Iida T; Kano M Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886 [TBL] [Abstract][Full Text] [Related]
3. Determinants of fixation in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab. Mathew R; Pearce E; Sivaprasad S Am J Ophthalmol; 2012 Mar; 153(3):490-496.e1. PubMed ID: 22071230 [TBL] [Abstract][Full Text] [Related]
4. Retinal blood flow in response to an intravitreal injection of ranibizumab for neovascular age-related macular degeneration. Micieli JA; Tsui E; Lam WC; Brent MH; Devenyi RG; Hudson C Acta Ophthalmol; 2012 Feb; 90(1):e13-20. PubMed ID: 21801339 [TBL] [Abstract][Full Text] [Related]
5. Retinal venular caliber predicts visual outcome after intravitreal ranibizumab injection treatments for neovascular AMD. Wickremasinghe SS; Busija L; Guymer RH; Wong TY; Qureshi S Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):37-41. PubMed ID: 22110075 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS; Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252 [TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670 [TBL] [Abstract][Full Text] [Related]
8. Same-day consecutive bilateral intravitreal injections of ranibizumab for the treatment of bilateral active choroidal neovascularization in age-related macular degeneration. Shah M; Amoaku WM Acta Ophthalmol; 2012 Sep; 90(6):e491-3. PubMed ID: 22269064 [No Abstract] [Full Text] [Related]
9. Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings. Cohen SY; Oubraham H; Uzzan J; Dubois L; Tadayoni R Retina; 2012 Sep; 32(8):1480-5. PubMed ID: 22258164 [TBL] [Abstract][Full Text] [Related]
10. Accuracy, precision and repeatability in preparing the intravitreal dose with a 1.0-cc syringe. Meyer CH; Liu Z; Brinkmann C; Rodrigues EB; Helb HM Acta Ophthalmol; 2012 Mar; 90(2):e165-6. PubMed ID: 21470379 [No Abstract] [Full Text] [Related]
11. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration. Rauch R; Weingessel B; Maca SM; Vecsei-Marlovits PV Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738 [TBL] [Abstract][Full Text] [Related]
12. Interobserver variability for retreatment indications after Ranibizumab loading doses in neovascular age-related macular degeneration. Framme C; Panagakis G; Walter A; Gamulescu MA; Herrmann W; Helbig H Acta Ophthalmol; 2012 Feb; 90(1):49-55. PubMed ID: 20716323 [TBL] [Abstract][Full Text] [Related]